[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‐dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Authors

Simron Singh

Published

June 1, 2024

Abstract

There are currently no standard first-line treatment options for patients with higher grade 2-3, well-differentiated, advanced, gastroenteropancreatic neuroendocrine tumours. We aimed to investigate the efficacy and safety of first-line [

Supporters

Support the authors with ResearchCoin

Journal

The Lancet

Topics

DOI

10.1016/s0140-6736(24)00701-3

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‐dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Authors

Simron Singh

Published

June 1, 2024

Abstract

Supporters

Support the authors with ResearchCoin

Journal

The Lancet

Topics

DOI

10.1016/s0140-6736(24)00701-3

Paper

Paper

Paper

Paper

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‐dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Abstract

Supporters

Journal

Topics

DOI

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‐dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study

Abstract

Supporters

Journal

Topics

DOI